Should I buy or sell Kodiak Sciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last year. There are currently 3 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" KOD shares. View KOD analyst ratings or view top-rated stocks .

What is Kodiak Sciences' stock price target for 2024?

7 brokerages have issued 12-month price targets for Kodiak Sciences' stock. Their KOD share price targets range from $2.00 to $12.00. On average, they predict the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 52.8% from the stock's current price. View analysts price targets for KOD or view top-rated stocks among Wall Street analysts .

How have KOD shares performed in 2024?

Kodiak Sciences' stock was trading at $3.04 at the beginning of 2024. Since then, KOD stock has increased by 18.4% and is now trading at $3.60. View the best growth stocks for 2024 here .

When is Kodiak Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our KOD earnings forecast .

How were Kodiak Sciences' earnings last quarter?

Kodiak Sciences Inc. (NASDAQ:KOD) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by $0.14.

What other stocks do shareholders of Kodiak Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include Quest Diagnostics (DGX) , Cronos Group (CRON) , Deere & Company (DE) , GrowGeneration (GRWG) , Immunomedics (IMMU) , Teck Resources (TECK) , Abbott Laboratories (ABT) , Ability (ABIL) , AbbVie (ABBV) and

When did Kodiak Sciences IPO?

Kodiak Sciences (KOD) raised $126 million in an initial public offering on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers.

Who are Kodiak Sciences' major shareholders?

Kodiak Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.25%). Insiders that own company stock include Bros Advisors Lp Baker, Jason Ehrlich , John A Borgeson and Victor Perlroth. View institutional ownership trends .

How do I buy shares of Kodiak Sciences?

Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KOD

Kodiak Sciences (KOD) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free KOD Stock Alerts

$3.60

-0.29 (-7.46%)

(As of 04/17/2024 ET)

Compare

Today's Range: $3.58
▼
$3.93
50-Day Range: $3.60
▼
$7.45
52-Week Range: $1.37
▼
$9.80

Volume: 607,667 shs
Average Volume: 858,836 shs
Market Capitalization: $189.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Get Kodiak Sciences alerts:

Kodiak Sciences MarketRank™ Stock Analysis

Analyst Rating: Reduce
1.71 Rating Score
Upside/Downside: 52.8% Upside
$5.50 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.87
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.34) to ($3.16) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.77 out of 5 stars

Medical Sector

401st out of 913 stocks

Biological Products, Except Diagnostic Industry

50th out of 136 stocks

2.9

Analyst's Opinion

Consensus Rating
Kodiak Sciences has received a consensus rating of Reduce. The company's average rating score is 1.71, and is based on 1 buy rating, 3 hold ratings, and 3 sell ratings.
Amount of Analyst Coverage
Kodiak Sciences has only been the subject of 2 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for KOD.

0.0

Dividend Strength

Dividend Yield
Kodiak Sciences does not currently pay a dividend.
Dividend Growth
Kodiak Sciences does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Kodiak Sciences has received a 73.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Kodiak Sciences is -0.87.

1.4

News and Social Media Coverage

News Sentiment
Kodiak Sciences has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Kodiak Sciences this week, compared to 2 articles on an average week.
Search Interest
Only 4 people have searched for KOD on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Kodiak Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kodiak Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
45.40% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Kodiak Sciences are expected to grow in the coming year, from ($4.34) to ($3.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kodiak Sciences is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kodiak Sciences is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kodiak Sciences has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About Kodiak Sciences Stock (NASDAQ:KOD)

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

KOD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KOD Stock News Headlines

April 17, 2024 | msn.com

Kodiak Sciences (KOD) Price Target Increased by 11.84% to 4.34

April 11, 2024 | finance.yahoo.com

Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely?

April 17, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

April 3, 2024 | yahoo.com

Alaska schools could buckle down on civics

March 30, 2024 | msn.com

Alaska Legislature boosts allowable payments from fund that covers fishers’ crew medical costs

March 30, 2024 | seekingalpha.com

Kodiak Sciences Inc. (KOD) Q4 2023 Earnings Call Transcript

March 30, 2024 | markets.businessinsider.com

Barclays Sticks to Their Sell Rating for Kodiak Sciences (KOD)

March 29, 2024 | finance.yahoo.com

Q4 2023 Kodiak Sciences Inc Earnings Call

April 17, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

March 29, 2024 | theguardian.com

Surge of new US-led oil and gas activity threatens to wreck Paris climate goals

March 28, 2024 | yahoo.com

Alutiiq museum in Kodiak celebrates the past to connect with the future

March 28, 2024 | finanznachrichten.de

Kodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

March 28, 2024 | marketwatch.com

Kodiak Sciences Shares Fall 24% on 4Q EPS Miss

March 28, 2024 | benzinga.com

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

March 28, 2024 | finance.yahoo.com

Kodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial Results

March 27, 2024 | msn.com

The 8 Best Alaska Cruises to Take in 2024

March 27, 2024 | benzinga.com

Preview: Kodiak Sciences's Earnings

February 24, 2024 | msn.com

State of Texas: Ruling sparks Paxton’s push to oust conservative judges on Court of Criminal Appeals

February 23, 2024 | msn.com

Agency asks public to name, get to know member of highly endangered Alaska whale population

February 16, 2024 | finance.yahoo.com

KOD Mar 2024 3.500 call

February 12, 2024 | finance.yahoo.com

Following a 25% decline over last year, recent gains may please Kodiak Sciences Inc. (NASDAQ:KOD) institutional owners

February 10, 2024 | usatoday.com

A female stingray at a NC aquarium becomes pregnant without a male mate. But how?

February 6, 2024 | bbc.com

The moment Jennifer Crumbley reacts to guilty verdict

February 6, 2024 | bbc.com

Drone video shows graffiti covering luxury high-rise in LA

February 6, 2024 | msn.com

Hot water failures, grease buildup: See January's Centre County restaurant inspections

February 4, 2024 | bbc.com

Taylor Swift/ Travis Kelce romance reaches White House

February 4, 2024 | msn.com

Yes, Colorado celebrates a frozen dead guy every year – here’s why

See More Headlines

Receive KOD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/17/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:KOD
CUSIP: N/A
CIK: 1468748
Web: kodiak.com
Phone: (650) 281-0850
Fax: N/A
Employees: 116
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.50
High Stock Price Target: $12.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +52.8%
Consensus Rating: Reduce
Rating Score (0-4): 1.71
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.96)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-260,490,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -80.20%
Return on Assets: -46.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.93
Quick Ratio: 6.93

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.07 per share
Price / Book: 0.71

Miscellaneous

Outstanding Shares: 52,509,000
Free Float: 28,670,000
Market Cap: $189.03 million
Optionable: Optionable
Beta: 2.15

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Victor Perlroth M.D. (Age 51)
Co-Founder, Chairman, CEO & President
Comp: $1.08M
Mr. John A. Borgeson CPA (Age 62)
M.B.A., Senior VP, CFO & Secretary
Comp: $667.52k
Dr. Michael S. Louie Ph.D.
Senior VP of Digital Transformation & Chief Information Officer
Dr. Hong Liang (Age 52)
Senior Vice President of Discovery Medicine
Comp: $300.71k
Dr. Stephen Raillard Ph.D.
Senior Vice President of Chemical Development & Manufacturing
Ms. Almas Qudrat M.Sc.
Senior Vice President of Quality Operations
Dr. J. Pablo Velazquez-Martin M.D.
Senior VP of Clinical Research & Development
Tracy Chien
VP & Corporate Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KOD Stock Analysis - Frequently Asked Questions

Should I buy or sell Kodiak Sciences stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last year. There are currently 3 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" KOD shares.
View KOD analyst ratings or view top-rated stocks.
What is Kodiak Sciences' stock price target for 2024?: 7 brokerages have issued 12-month price targets for Kodiak Sciences' stock. Their KOD share price targets range from $2.00 to $12.00. On average, they predict the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 52.8% from the stock's current price.
View analysts price targets for KOD or view top-rated stocks among Wall Street analysts.
How have KOD shares performed in 2024?: Kodiak Sciences' stock was trading at $3.04 at the beginning of 2024. Since then, KOD stock has increased by 18.4% and is now trading at $3.60.
View the best growth stocks for 2024 here.
When is Kodiak Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our KOD earnings forecast.
How were Kodiak Sciences' earnings last quarter?: Kodiak Sciences Inc. (NASDAQ:KOD) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by $0.14.

What other stocks do shareholders of Kodiak Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include Quest Diagnostics (DGX), Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and
When did Kodiak Sciences IPO?: Kodiak Sciences (KOD) raised $126 million in an initial public offering on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers.
Who are Kodiak Sciences' major shareholders?: Kodiak Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.25%). Insiders that own company stock include Bros Advisors Lp Baker, Jason Ehrlich, John A Borgeson and Victor Perlroth.
View institutional ownership trends.
How do I buy shares of Kodiak Sciences?: Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KOD) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Kodiak Sciences (KOD) Stock Price, News & Analysis

Kodiak Sciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Kodiak Sciences Stock (NASDAQ:KOD)

KOD Stock Price History

KOD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KOD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™